Vysov 50 Mg (Vildagliptin)

Product Overview

Vysov 50 Mg is a prescription oral antidiabetic medication that contains the DPP‑4 inhibitor vildagliptin. Produced by Cipla Limited, each strip holds 15 film‑coated tablets, each delivering a precise 50 mg dose of the active ingredient. The product is specifically indicated for the treatment of type 2 diabetes mellitus when diet and exercise alone do not achieve adequate glycemic control. Vysov is formulated to provide consistent plasma concentrations throughout the day, supporting sustained glucose regulation when used as part of a comprehensive diabetes management plan.

What is Vysov 50 Mg (Vildagliptin)

Vildagliptin belongs to the class of dipeptidyl peptidase‑4 (DPP‑4) inhibitors. The drug functions by blocking the DPP‑4 enzyme, which rapidly degrades incretin hormones such as glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By preserving these hormones, Vysov enhances glucose‑dependent insulin secretion from pancreatic β‑cells and suppresses inappropriate glucagon release from α‑cells, resulting in lowered fasting and post‑prandial blood glucose levels without a high risk of hypoglycemia. This mechanism distinguishes DPP‑4 inhibitors from other oral antidiabetic agents.

Uses and Benefits

The primary therapeutic use of Vysov 50 Mg is to improve glycemic control in adults diagnosed with type 2 diabetes mellitus. Clinical trials have shown that, when combined with a healthy diet and regular physical activity, the medication can reduce glycated hemoglobin (HbA1c) by approximately 0.5 to 1.0 % over 24 weeks. In addition to its glucose‑lowering effect, Vysov is associated with weight neutrality, meaning patients typically do not experience significant weight gain or loss. The drug also carries a low propensity to cause hypoglycemia compared with sulfonylureas, making it a suitable option for many patients, including those who are elderly or at risk for low blood sugar episodes. Vysov can be prescribed as monotherapy or in combination with other oral agents such as metformin or sulfonylureas, as well as with insulin when additional therapy is required.

How It Works

Vildagliptin exerts its antidiabetic effect through selective inhibition of the DPP‑4 enzyme. DPP‑4 normally cleaves incretin hormones shortly after their release, limiting their activity. By inhibiting this enzyme, Vysov prolongs the lifespan of GLP‑1 and GIP, leading to enhanced stimulation of insulin secretion in the presence of elevated glucose and suppression of glucagon when glucose levels fall. This glucose‑dependent action means that insulin release is triggered only when blood glucose is high, reducing the likelihood of excessively low blood sugar. Additionally, the prolonged activity of incretins contributes to modest improvements in β‑cell function over time, potentially offering disease‑modifying benefits beyond mere glucose control.

Dosage Guidelines

The recommended initial dosage of Vysov 50 Mg is one tablet taken orally once daily, with or without food. The dosing schedule should be maintained at the same time each day to ensure steady drug levels. In patients with mild to moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥30 mL/min/1.73 m²), no dose adjustment is necessary. However, for those with severe renal impairment (eGFR <30 mL/min/1.73 m²), the dose should be reduced to 25 mg once daily, which is half the standard strength. Hepatic impairment does not require a dosage change. Vysov is not indicated for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double up on doses to compensate for a missed one. Routine monitoring of renal function is advised at intervals appropriate to the patient’s clinical status.

Side Effects

Adverse reactions to Vysov are generally mild and transient. The most frequently reported side effects include nasopharyngitis, headache, and urinary tract infections. Less common but clinically important events may involve pancreatitis, elevations in liver enzymes, and hypersensitivity reactions such as skin rash or angioedema. Rarely, patients may experience hypoglycemia when Vysov is used in combination with insulin or sulfonylureas, particularly if dosage adjustments are not made. In the event of persistent abdominal pain, severe joint pain, or signs of an allergic reaction (e.g., swelling of the face, lips, or tongue), patients should discontinue the medication and seek immediate medical attention. Regular liver function tests are recommended for patients with pre‑existing hepatic conditions.

Warnings and Precautions

Before initiating therapy with Vysov, healthcare providers should assess renal function and be vigilant for signs of pancreatitis. The medication should be used with caution in patients with a history of hypersensitivity to vildagliptin or any excipients in the formulation. Concomitant use of strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) may alter drug exposure, and dose modifications may be required. Pregnant women should only use Vysov if the potential maternal benefit justifies the possible fetal risk, and breastfeeding is not recommended during treatment. Patients should be advised to avoid excessive alcohol consumption, which can increase the risk of hepatic complications. Routine monitoring of blood glucose, renal parameters, and liver enzymes is recommended at intervals determined by the clinician.

Frequently Asked Questions